Drugs / Trivalent oral attenuated live poliomyelitis vaccine against type 1, type 2 and type 3
Trivalent oral attenuated live poliomyelitis vaccine against type 1, type 2 and type 3
also known as
tOPV
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03614702 | Sep 2015 → Aug 2016 | poliomyelitis | Institute of Medical Biology, Chinese Academy of Medical Sciences | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trivalent oral attenuated live poliomyelitis vaccine against type 1, type 2 and type 3 | “tOPV (Candy): Trivalent oral attenuated live poliomyelitis vaccine against type 1, type 2 and type 3 in Dragee Candy (Human Diploid Cell) Produced by Beijing Tiantan Biological...” NCT03614702 ↗ |
| Known as | tOPV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03614702 ↗ |
| Modality | Vaccine | “Trivalent oral attenuated live poliomyelitis vaccine against type 1, type 2 and type 3” NCT03614702 ↗ |
| Route | Oral | “followed by 1-dose tOPV(Candy) through mouth” NCT03614702 ↗ |